BioInvent International AB (publ) (LON:0H22)

Market Cap	121.24M +3.9%
Revenue (ttm)	18.26M +406.9%
Net Income	-26.83M
EPS	-0.41
Shares Out	n/a
PE Ratio	n/a
Forward PE	10.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1,215
Open	n/a
Previous Close	23.25
Day's Range	n/a
52-Week Range	21.93 - 40.45
Beta	-0.03
RSI	34.31
Earnings Date	Feb 26, 2026

About LON:0H22

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company’s drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an anti-FcyRIIB antibody in Phase 1/2a trial for the treatment of non-Hodgkin’s lymphoma, as well as Phase 1/2a trial to treat advanced solid tumors; BI-19...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 124
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0H22

Financial Performance

In 2025, LON:0H22's revenue was 226.50 million, an increase of 406.86% compared to the previous year's 44.69 million. Losses were -332.86 million, -22.48% less than in 2024.

Financial numbers in SEK